Neurology

Dermira pulling plug on acne drug after phase 3 failure Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after it failed to meet its primary endpoints in a pair of phase 3 trials. The drug was tested in patients aged nine and older with moderate to severe acne vulgaris. The mechanism of action of the drug was on targeting the overproduction of sebum. Stem cells providing insight on potential anti-Alzheimer’s compound It is found that toxic deposits of the proteins amyloid beta and tau in the brain have been associated with Alzheimer’s disease, but the exact role of these proteins in causing dementia is still unknown. A gr...